Eisai Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

E2007-G000-208

Study Overview

E2007
perampanel
NCT00416195, EU CTR 2006-003702-26
Dec 2006 - Mar 2008
Refractory Partial Seizures
Percentage of Responders During the Maintenance Phase [ Time Frame: Day 85 through Day 112 ]
A patient is a responder if she/he experiences a 50% or greater reduction in seizure frequency from the baseline phase.

  • Males and females (age 18 years to 70 years)

  • Completed

  • Phase 2

  • Latvia

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR